Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial
Christopher SorliBillings Clinic Research Center, Billings, MT, USA. Electronic address: [email protected]Shin‐ichi HarashimaGraduate School of Medicine, Kyoto University, Kyoto, JapanGeorge TsoukasDepartment of Medicine, McGill University, Montreal, QC, CanadaJeffrey UngerCatalina Research Institute, Chino, CA, USAJulie Derving KarsbølNovo Nordisk A/S, Søborg, DenmarkThomas K. HansenNovo Nordisk A/S, Søborg, DenmarkStephen C. BainSchool of Medicine, Swansea University, Swansea, Wales, UK
2017en
ABI
Аннотация
Аннотация отсутствует.
Идентификаторы
Цитирования и источники
Цитирований: 2Использованных источников: 0